Brian Orelli, biotech contributor and writer at The Motley Fool, joins the channel to discuss why he owns Novocure (NVCR -2.43%) stock. Check out his reasoning in this video!

*Stock prices used were the midday prices of Aug. 10, 2022. The video was published on Aug. 21, 2022.